Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CFDA Approves BGI’s Prenatal DNA Test, Reversing Ban on Genetic Testing

publication date: Jul 8, 2014
BGI Diagnostics, a division of BGI-Shenzhen, announced that its non-invasive prenatal test, which uses a sample of maternal blood, was approved by the CFDA. The NIFTY™ kit tests for chromosomal abnormalities at Trisomy 21 (Down Syndrome), 13 (Patau Syndrome) and 18 (Edwards Syndrome). In April, the CFDA banned all clinical genetic testing, except for projects approved by the government. It wasn’t clear, after the announcement, if any projects would ever be approved. By allowing BGI to market its test, the government has shown that it wants to control DNA tests, not stop them. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital